Scripsamerica Stock Performance
| SCRCQ Stock | USD 0.0001 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and ScripsAmerica are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days ScripsAmerica has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental indicators, ScripsAmerica is not utilizing all of its potentials. The newest stock price agitation, may contribute to short-term losses for the retail investors. ...more
ScripsAmerica |
ScripsAmerica Relative Risk vs. Return Landscape
If you would invest 0.01 in ScripsAmerica on September 26, 2025 and sell it today you would earn a total of 0.00 from holding ScripsAmerica or generate 0.0% return on investment over 90 days. ScripsAmerica is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than ScripsAmerica, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
ScripsAmerica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ScripsAmerica's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as ScripsAmerica, and traders can use it to determine the average amount a ScripsAmerica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| SCRCQ |
Based on monthly moving average ScripsAmerica is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ScripsAmerica by adding ScripsAmerica to a well-diversified portfolio.
ScripsAmerica Fundamentals Growth
ScripsAmerica Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of ScripsAmerica, and ScripsAmerica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ScripsAmerica Pink Sheet performance.
| Return On Asset | -0.53 | |||
| Profit Margin | (0.13) % | |||
| Operating Margin | (0.09) % | |||
| Current Valuation | 1.82 M | |||
| Shares Outstanding | 141.08 M | |||
| Price To Earning | (0.02) X | |||
| Revenue | 30.85 M | |||
| EBITDA | (5.19 M) | |||
| Cash And Equivalents | 160.85 K | |||
| Total Debt | 1.07 M | |||
| Debt To Equity | (2.94) % | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | 697.63 K | |||
| Earnings Per Share | (0.04) X | |||
| Total Asset | 5.64 M | |||
| Retained Earnings | (21.67 M) | |||
| Current Asset | 5.32 M | |||
| Current Liabilities | 7.95 M | |||
About ScripsAmerica Performance
Assessing ScripsAmerica's fundamental ratios provides investors with valuable insights into ScripsAmerica's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ScripsAmerica is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
ScripsAmerica, Inc. develops and sells non-sterile topical and transdermal pain creams. On February 8, 2017, the voluntary petition of ScripsAmerica, Inc. for reorganization under Chapter 11 was converted to Chapter 7. Scripsamerica operates under Pharmaceutical Retailers classification in the United States and is traded on OTC Exchange. It employs 21 people.Things to note about ScripsAmerica performance evaluation
Checking the ongoing alerts about ScripsAmerica for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for ScripsAmerica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ScripsAmerica generated a negative expected return over the last 90 days | |
| ScripsAmerica has some characteristics of a very speculative penny stock | |
| ScripsAmerica has accumulated 1.07 M in total debt. ScripsAmerica has a current ratio of 0.61, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist ScripsAmerica until it has trouble settling it off, either with new capital or with free cash flow. So, ScripsAmerica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ScripsAmerica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ScripsAmerica to invest in growth at high rates of return. When we think about ScripsAmerica's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 30.85 M. Net Loss for the year was (4.73 M) with profit before overhead, payroll, taxes, and interest of 27.6 M. |
- Analyzing ScripsAmerica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ScripsAmerica's stock is overvalued or undervalued compared to its peers.
- Examining ScripsAmerica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ScripsAmerica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ScripsAmerica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ScripsAmerica's pink sheet. These opinions can provide insight into ScripsAmerica's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ScripsAmerica Pink Sheet Analysis
When running ScripsAmerica's price analysis, check to measure ScripsAmerica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ScripsAmerica is operating at the current time. Most of ScripsAmerica's value examination focuses on studying past and present price action to predict the probability of ScripsAmerica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ScripsAmerica's price. Additionally, you may evaluate how the addition of ScripsAmerica to your portfolios can decrease your overall portfolio volatility.